Systemic Mastocytosis

Advances in Immunology

Volumn 89, Issue , 2006, Pages 169-243

  Robyn, Jamie ^a   Metcalfe, Dean D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ADRENALIN; ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; AP 23848; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLADRIBINE; CROMOGLYCATE DISODIUM; CYCLOSPORIN A; CYTARABINE; DASATINIB; DAUNORUBICIN; DOXORUBICIN; GLUCOCORTICOID; IMATINIB; IMD 0354; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; MIDOSTAURIN; NILOTINIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RECOMBINANT ALPHA INTERFERON; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VITAMIN D;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALLERGY; ANAPHYLAXIS; ANESTHESIA COMPLICATION; ANGIOGENESIS; ANOREXIA; BLOOD CELL COUNT; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BONE PAIN; CELL CULTURE; CELL FUNCTION; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CYTOLOGY; CYTOREDUCTIVE SURGERY; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED CANCER; ENZYME ACTIVITY; ENZYME POLYMORPHISM; EPIDEMIOLOGICAL DATA; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYPERPLASIA; HYPOTENSION; INFECTION COMPLICATION; INNATE IMMUNITY; MAST CELL; MUSCULOSKELETAL PAIN; MYALGIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OSTEOPENIA; PANCYTOPENIA; PATHOGENESIS; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SPLENECTOMY; SYSTEMIC MASTOCYTOSIS; TREATMENT INDICATION;

ANIMALS; HUMANS; MAST CELLS; MASTOCYTOSIS, SYSTEMIC;

EID: 33646205696     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(05)89005-4     Document Type: Review

References (392)

1. Achord J.L., and Langford H. The effect of cimetidine and propantheline on the symptoms of a patient with systemic mastocytosis. Am. J. Med. 69 (1980) 610-614
2. Agosti V., Corbacioglu S., Ehlers I., Waskow C., Sommer G., Berrozpe G., Kissel H., Tucker C.M., Manova K., Moore M.A., Rodewald H.R., and Besmer P. Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J. Exp. Med. 199 (2004) 867-878
3. Akin C., Brockow K., D'Ambrosio C., Kirshenbaum A.S., Ma Y., Longley B.J., and Metcalfe D.D. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-Kit. Exp. Hematol. 31 (2003) 686-692
4. Akin C., Fumo G., Yavuz A.S., Lipsky P.E., Neckers L., and Metcalfe D.D. A novel form of mastocytosis associated with a transmembrane c-Kit mutation and response to imatinib. Blood 103 (2004) 3222-3225
5. Akin C., and Metcalfe D.D. The biology of Kit in disease and the application of pharmacogenetics. J. Allergy Clin. Immunol. 114 (2004) 13-19
6. Akin C., and Metcalfe D.D. Surrogate markers of disease in mastocytosis. Int. Arch. Allergy Immunol. 127 (2002) 133-136
7. Akin C., Schwartz L.B., Kitoh T., Obayashi H., Worobec A.S., Scott L.M., and Metcalfe D.D. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: Relationships to disease severity and bone marrow pathology. Blood 96 (2000) 1267-1273
8. Akin C., Scott L.M., and Metcalfe D.D. Slowly progressive systemic mastocytosis with high masT cell burden and no evidence of a non-masT cell hematologic disorder: An example of a smoldering case?. Leuk. Res. 25 (2001) 635-638
9. Alexander R.R. Disodium cromoglycate in the treatment of systemic mastocytosis involving only bone. Acta Haematol. 74 (1985) 108-110
10. Alter S.C., Kramps J.A., Janoff A., and Schwartz L.B. Interactions of human mast cell tryptase with biological protease inhibitors. Arch. Biochem. Biophys. 276 (1990) 26-31
11. Arm J.P., and Lee T.H. Sulphidopeptide leukotrienes in asthma. Clin. Sci. (Lond.) 84 (1993) 501-510
12. Arock M., Schneider E., Boissan M., Tricottet V., and Dy M. Differentiation of human basophils: An overview of recent advances and pending questions. J. Leukoc. Biol. 71 (2002) 557-564
13. Asai K., Kitaura J., Kawakami Y., Yamagata N., Tsai M., Carbone D.P., Liu F.T., Galli S.J., and Kawakami T. Regulation of mast cell survival by IgE. Immunity 14 (2001) 791-800
14. Austen K.F. Systemic mastocytosis. N. Engl. J. Med. 326 (1992) 639-640
15. Avila N.A., Ling A., Metcalfe D.D., and Worobec A.S. Mastocytosis: Magnetic resonance imaging patterns of marrow disease. Skeletal Radiol. 27 (1998) 119-126
16. Azizkhan R.G., Azizkhan J.C., Zetter B.R., and Folkman J. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J. Exp. Med. 152 (1980) 931-944
17. Baghestanian M., Bankl H., Sillaber C., Beil W.J., Radaszkiewicz T., Fureder W., Preiser J., Vesely M., Schernthaner G., Lechner K., and Valent P. A case of malignant mastocytosis with circulating mast cell precursors: Biologic and phenotypic characterization of the malignant clone. Leukemia 10 (1996) 159-166
18. Bain B. The idiopathic hypereosinophilic syndrome and eosinophilic leukemias. Haematologica 89 (2004) 133-137
19. Bain B.J. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am. J. Hematol. 77 (2004) 82-85
20. Barnes P.J., Chung K.F., and Page C.P. Platelet-activating factor as a mediator of allergic disease. J. Allergy Clin. Immunol. 81 (1988) 919-934
21. Barrett A.J. Mechanisms of the graft-versus-leukemia reaction. Stem Cells 15 (1997) 248-258
22. Barrett A.J., and Malkovska V. Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies. Br. J. Haematol. 93 (1996) 754-761
23. Barrett A.J., and van R.F. Graft-versus-leukaemia. Baillieres Clin. Haematol. 10 (1997) 337-355
24. Barrett J., and Childs R. Non-myeloablative stem cell transplants. Br. J. Haematol. 111 (2000) 6-17
25. Beghini A., Peterlongo P., Ripamonti C.B., Larizza L., Cairoli R., Morra E., and Mecucci C. C-kit mutations in core binding factor leukemias. Blood 95 (2000) 726-727
26. Beghini A., Tibiletti M.G., Roversi G., Chiaravalli A.M., Serio G., Capella C., and Larizza L. Germ line mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 92 (2001) 657-662
27. Benhamou M., Bonnerot C., Fridman W.H., and Daeron M. Molecular heterogeneity of murine mast cell Fc gamma receptors. J. Immunol. 144 (1990) 3071-3077
28. Benyon R.C., Robinson C., and Church M.K. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. Br. J. Pharmacol. 97 (1989) 898-904
29. Bischoff S.C., Sellge G., Lorentz A., Sebald W., Raab R., and Manns M.P. IL-4 enhances proliferation and mediator release in mature human mast cells. Proc. Natl. Acad. Sci. USA 96 (1999) 8080-8085
30. Blechman J.M., Lev S., Barg J., Eisenstein M., Vaks B., Vogel Z., Givol D., and Yarden Y. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80 (1995) 103-113
31. Blume-Jensen P., Janknecht R., and Hunter T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8 (1998) 779-782
32. Boesiger J., Tsai M., Maurer M., Yamaguchi M., Brown L.F., Claffey K.P., Dvorak H.F., and Galli S.J. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J. Exp. Med. 188 (1998) 1135-1145
33. Bonifazi F., de V.A., Rosti G., Guilhot F., Guilhot J., Trabacchi E., Hehlmann R., Hochhaus A., Shepherd P.C., Steegmann J.L., Kluin-Nelemans H.C., Thaler J., Simonsson B., Louwagie A., Reiffers J., Mahon F.X., Montefusco E., Alimena G., Hasford J., Richards S., Saglio G., Testoni N., Martinelli G., Tura S., and Baccarani M. Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood 98 (2001) 3074-3081
34. Bonnet P., Smadja C., Szekely A.M., Delage Y., Calmus Y., Poupon R., and Franco D. Intractable ascites in systemic mastocytosis treated by portal diversion. Dig. Dis. Sci. 32 (1987) 209-213
35. Bono P., Krause A., von M.M., Heinrich M.C., Blanke C.D., Dimitrijevic S., Demetri G.D., and Joensuu H. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 103 (2004) 2929-2935
36. Borgeat A., and Ruetsch Y.A. Anesthesia in a patient with malignant systemic mastocytosis using a total intravenous anesthetic technique. Anesth. Analg. 86 (1998) 442-444
37. Brizzi M.F., Zini M.G., Aronica M.G., Blechman J.M., Yarden Y., and Pegoraro L. Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase. J. Biol. Chem. 269 (1994) 31680-31684
38. Brockow K., Akin C., Huber M., and Metcalfe D.D. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin. Immunol. 115 (2005) 216-223
39. Brockow K., Akin C., Huber M., Scott L.M., Schwartz L.B., and Metcalfe D.D. Levels of masT cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal masT cell numbers and masT cell tryptase. J. Allergy Clin. Immunol. 109 (2002) 82-88
40. Broudy V.C., Lin N.L., Liles W.C., Corey S.J., O'Laughlin B., Mou S., and Linnekin D. Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. Blood 94 (1999) 1979-1986
41. Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br. J. Dermatol. 138 (1998) 489-495
42. Butterfield J.H., Weiler D., Dewald G., and Gleich G.J. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk. Res. 12 (1988) 345-355
43. Casassus P., Caillat-Vigneron N., Martin A., Simon J., Gallais V., Beaudry P., Eclache V., Laroche L., Lortholary P., Raphael M., Guillevin L., and Lortholary O. Treatment of adult systemic mastocytosis with interferon-alpha: Results of a multicentre phase II trial on 20 patients. Br. J. Haematol. 119 (2002) 1090-1097
44. Castells M., and Austen K.F. Mastocytosis: Mediator-related signs and symptoms. Int. Arch. Allergy Immunol. 127 (2002) 147-152
45. Castells M.C. Mastocytosis: Classification, diagnosis, and clinical presentation. Allergy Asthma Proc. 25 (2004) 33-36
46. Caughey G.H., Raymond W.W., and Wolters P.J. Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim. Biophys. Acta 1480 (2000) 245-257
47. Chang A., Tung R.C., Schlesinger T., Bergfeld W.F., Dijkstra J., and Kahn T.A. Familial cutaneous mastocytosis. Pediatr. Dermatol. 18 (2001) 271-276
48. Cherner J.A., Jensen R.T., Dubois A., O'Dorisio T.M., Gardner J.D., and Metcalfe D.D. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study 236. Gastroenterology 95 (1988) 657-667
49. Chott A., Guenther P., Huebner A., Selzer E., Parwaresch R.M., Horny H.P., and Valent P. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am. J. Surg. Pathol. 27 (2003) 1013-1019
50. Church M.K., and Levi-Schaffer F. The human mast cell. J. Allergy Clin. Immunol. 99 (1997) 155-160
51. Clemens M.J. Interferons and apoptosis. J. Interferon Cytokine Res. 23 (2003) 277-292
52. Coleman J.W. Nitric oxide: A regulator of mast cell activation and mast cell-mediated inflammation. Clin. Exp. Immunol. 129 (2002) 4-10
53. Coleman M.A., Liberthson R.R., Crone R.K., and Levine F.H. General anesthesia in a child with urticaria pigmentosa. Anesth. Analg. 59 (1980) 704-706
54. Compton S.J., Cairns J.A., Holgate S.T., and Walls A.F. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: Tryptase induces expression of mRNA for IL-1 beta and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. J. Immunol. 161 (1998) 1939-1946
55. Cools J., De Angelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., and Gilliland D.G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348 (2003) 1201-1214
56. Cools J., Stover E.H., Wlodarska I., Marynen P., and Gilliland D.G. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr. Opin. Hematol. 11 (2004) 51-57
57. Corbin A.S., Demehri S., Griswold I.J., Wang Y., Metcalf III C.A., Sundaramoorthi R., Shakespeare W.C., Snodgrass J., Wardwell S., Dalgarno D., Iuliucci J., Sawyer T.K., Heinrich M.C., Druker B.J., and Deininger M.W. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood 106 (2005) 227-234
58. Corbin A.S., Griswold I.J., La R.P., Yee K.W., Heinrich M.C., Reimer C.L., Druker B.J., and Deininger M.W. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104 (2004) 3754-3757
59. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22 (2004) 3813-3825
60. Cutler R.L., Liu L., Damen J.E., and Krystal G. Multiple cytokines induce the tyrosine phosphorylation of Shc and its association with Grb2 in hemopoietic cells. J. Biol. Chem. 268 (1993) 21463-21465
61. Czarnetzki B.M., Algermissen B., Jeep S., Haas N., Nurnberg W., Muller K., and Kropp J.D. Interferon treatment of patients with chronic urticaria and mastocytosis. J. Am. Acad. Dermatol. 30 (1994) 500-501
62. D'Ambrosio C., Akin C., Wu Y., Magnusson M.K., and Metcalfe D.D. Gene expression analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers. J. Allergy Clin. Immunol. 112 (2003) 1162-1170
63. Daeron M., Malbec O., Latour S., Arock M., and Fridman W.H. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J. Clin. Invest. 95 (1995) 577-585
64. Daley T., Metcalfe D.D., and Akin C. Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin. Blood 98 (2001) 880-882
65. Dalton R., Chan L., Batten E., and Eridani S. Mast cell leukaemia: Evidence for bone marrow origin of the pathological clone. Br. J. Haematol. 64 (1986) 397-406
66. Davis B.J., Flanagan B.F., Gilfillan A.M., Metcalfe D.D., and Coleman J.W. Nitric oxide inhibits IgE-dependent cytokine production and Fos and Jun activation in mast cells. J. Immunol. 173 (2004) 6914-6920
67. DeBerry C., Mou S., and Linnekin D. Stat1 associates with c-Kit and is activated in response to stem cell factor. Biochem. J. 327 Pt 1 (1997) 73-80
68. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91 (2004) 1-30
69. Duensing A., Heinrich M.C., Fletcher C.D., and Fletcher J.A. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest. 22 (2004) 106-116
70. Echtenacher B., Mannel D.N., and Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381 (1996) 75-77
71. Efrati P., Klajman A., and Spitz H. Mast cell leukemia? Malignant mastocytosis with leukemia-like manifestations. Blood 12 (1957) 869-882
72. Ehrlich P. Beitrage zur theoretic and praxis de histologischer farbung (1878), University of Leipzig, Leipzig, Germany
73. Ellis J.M. Urticaria Pigmentosa: A report of a case with autopsy. Arch. Pathol. 48 (1949) 426
74. Escribano L., Akin C., Castells M., Orfao A., and Metcalfe D.D. Mastocytosis: Current concepts in diagnosis and treatment. Ann. Hematol. 81 (2002) 677-690
75. Escribano L., az-Agustin B., Bellas C., Navalon R., Nunez R., Sperr W.R., Schernthaner G.H., Valent P., and Orfao A. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk. Res. 25 (2001) 563-570
76. Escribano L., az-Agustin B., Lopez A., Nunez L.R., Garcia-Montero A., Almeida J., Prados A., Angulo M., Herrero S., and Orfao A. Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin. Cytom. 58 (2004) 1-8
77. Escribano L., Orfao A., Villarrubia J., az-Agustin B., Cervero C., Rios A., Velasco J.L., Ciudad J., Navarro J.L., and San Miguel J.F. Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathological bone marrow samples. Anal. Cell Pathol. 16 (1998) 151-159
78. Feger F., Ribadeau D.A., Leriche L., Valent P., and Arock M. Kit and c-Kit mutations in mastocytosis: A short overview with special reference to novel molecular and diagnostic concepts. Int. Arch. Allergy Immunol. 127 (2002) 110-114
79. Fiehn C., Prummer O., Gallati H., Heilig B., and Hunstein W. Treatment of systemic mastocytosis with interferon-gamma: Failure after appearance of anti-IFN-gamma antibodies. Eur. J. Clin. Invest. 25 (1995) 615-618
80. Florian S., Krauth M.T., Simonitsch-Klupp I., Sperr W.R., Fritsche-Polanz R., Sonneck K., Fodinger M., Agis H., Bohm A., Wimazal F., Horny H.P., and Valent P. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int. Arch. Allergy Immunol. 136 (2005) 273-280
81. Fodinger M., Fritsch G., Winkler K., Emminger W., Mitterbauer G., Gadner H., Valent P., and Mannhalter C. Origin of human mast cells: Development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 84 (1994) 2954-2959
82. Folkman J. Regulation of angiogenesis: A new function of heparin. Biochem. Pharmacol. 34 (1985) 905-909
83. Fonga-Djimi H.S., Gottrand F., Bonnevalle M., and Farriaux J.P. A fatal case of portal hypertension complicating systemic mastocytosis in an adolescent. Eur. J. Pediatr. 154 (1995) 819-821
84. Friedman B., Darling G., Norton J., Hamby L., and Metcalfe D. Splenectomy in the management of systemic mast cell disease 205. Surgery 107 (1990) 94-100
85. Frieri M., Alling D.W., and Metcalfe D.D. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. Am. J. Med. 78 (1985) 9-14
86. Fritsche-Polanz R., Jordan J.H., Feix A., Sperr W.R., Sunder-Plassmann G., Valent P., and Fodinger M. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol. 113 (2001) 357-364
87. Fukao T., Yamada T., Tanabe M., Terauchi Y., Ota T., Takayama T., Asano T., Takeuchi T., Kadowaki T., Hata J.J., and Koyasu S. Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat. Immunol. 3 (2002) 295-304
88. Fumo G., Akin C., Metcalfe D.D., and Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 103 (2004) 1078-1084
89. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., Sugahara H., Butterfield J.H., Ashman L.K., and Kanayama Y. Identification of mutations in the coding sequence of the proto-oncogene c-Kit in a human mast cell leukemia cell line causing ligand-independent activation of c-Kit product. J. Clin. Invest. 92 (1993) 1736-1744
90. Galli S.J., and Kitamura Y. Genetically masT cell-deficient W/Wv and Sl/Sld mice. Their value for the analysis of the roles of mast cells in biologic responses in vivo. Am. J. Pathol. 127 (1987) 191-198
91. Galli S.J., Tsai M., Wershil B.K., Tam S.Y., and Costa J.J. Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-Kit receptor. Int. Arch. Allergy Immunol. 107 (1995) 51-53
92. Gari M., Goodeve A., Wilson G., Winship P., Langabeer S., Linch D., Vandenberghe E., Peake I., and Reilly J. c-Kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br. J. Haematol. 105 (1999) 894-900
93. Gaudry M., Bregerie O., Andrieu V., El B.J., Pocidalo M.A., and Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 90 (1997) 4153-4161
94. Genovese A., Spadaro G., Triggiani M., and Marone G. Clinical advances in mastocytosis. Int. J. Clin. Lab Res. 25 (1995) 178-188
95. Gilliland G., Cools J., Stover E.H., Wlodarska I., and Marynen P. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis. Hematol. J. 5 Suppl. 3 (2004) S133-S137
96. Goemans B.F., Zwaan C., Miller M., Zimmermann M., Harlow A., Meshinchi S., Loonen A.H., Hahlen K., Reinhardt D., Creutzig U., Kaspers G.J., and Heinrich M.C. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19 (2000) 1536-1542
97. Goldstein S.M., Kaempfer C.E., Kealey J.T., and Wintroub B.U. Human mast cell carboxypeptidase. Purification and characterization. J. Clin. Invest. 83 (1989) 1630-1636
98. Gommerman J.L., Sittaro D., Klebasz N.Z., Williams D.A., and Berger S.A. Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential. Blood 96 (2000) 3734-3742
99. Gonera R.K., Oranje W.A., and Wolffenbuttel B.H. Shock of unknown origin-think of mastocytosis!. Neth. J. Med. 50 (1997) 165-169
100. Goodman G.R., Beutler E., and Saven A. Cladribine in the treatment of hairy-cell leukaemia. Best. Pract. Res. Clin. Haematol. 16 (2003) 101-116
101. Gordon J.R. TGFbeta1 and TNFalpha secreted by mast cells stimulated via the FcepsilonRI activate fibroblasts for high-level production of monocyte chemoattractant protein-1 (MCP-1). Cell Immunol. 201 (2000) 42-49
102. Gordon J.R., and Galli S.J. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 346 (1990) 274-276
103. Gotlib J., Berube C., Growney J.D., Chen C.C., George T.I., Williams C., Kajiguchi T., Ruan J., Lilleberg S.L., Durocher J.A., Lichy J.H., Wang Y., Cohen P.S., Arber D., Heinrich M.C., Neckers L., Galli S.J., Gilliland D.G., and Coutre S.E. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106 (2000) 2865-2870
104. Gotlib J., Cools J., Malone III J.M., Schrier S.L., Gilliland D.G., and Coutre S.E. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood 103 (2004) 2879-2891
105. Gotoh A., Takahira H., Mantel C., Litz-Jackson S., Boswell H.S., and Broxmeyer H.E. Steel factor induces serine phosphorylation of Stat3 in human growth factor-dependent myeloid cell lines. Blood 88 (1996) 138-145
106. Granerus G., Lonnqvist B., and Roupe G. No relationship between histamine release measured as metabolite excretion in the urine, and serum levels of mast cell specific tryptase in mastocytosis. Agents Actions 41 Spec No (1994) C127-C128
107. Greenblatt E.P., and Chen L. Urticaria pigmentosa: An anesthetic challenge. J. Clin. Anesth. 2 (1990) 108-115
108. Grossman R.M., Krueger J., Yourish D., Granelli-Piperno A., Murphy D.P., May L.T., Kupper T.S., Sehgal P.B., and Gottlieb A.B. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA 86 (1989) 6367-6371
109. Growney J.D., Clark J.J., Adelsperger J., Stone R., Fabbro D., Griffin J.D., and Gilliland D.G. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106 (2005) 721-724
110. Grundfest S., Cooperman A.M., Ferguson R., and Benjamin S. Portal hypertension associated with systemic mastocytosis and splenomegaly. Gastroenterology 78 (1980) 370-373
111. Grutzkau A., Kruger-Krasagakes S., Baumeister H., Schwarz C., Kogel H., Welker P., Lippert U., Henz B.M., and Moller A. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: Implications for the biological significance of VEGF206. Mol. Biol. Cell 9 (1998) 875-884
112. Guenther P.P., Huebner A., Sobottka S.B., Neumeister V., Weissbach G., Todt H., and Parwaresch R. Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J. Pediatr. Hematol. Oncol. 23 (2001) 134-138
113. Guo X., Schrader K.A., Xu Y., and Schrader J.W. Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras. Oncogene 24 (2005) 2330-2342
114. Hagen W., Schwarzmeier J., Walchshofer S., Zojer N., Chott A., Sillaber C., Ackermann J., Simonitsch I., Buhring H.J., Drach J., Lechner K., Horny H.P., and Valent P. A case of bone marrow mastocytosis associated with multiple myeloma. Ann. Hematol. 76 (1998) 167-174
115. Hallek M., Druker B., Lepisto E.M., Wood K.W., Ernst T.J., and Griffin J.D. Granulocyte-macrophage colony-stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor-dependent hematopoietic cell line. J. Cell Physiol. 153 (1992) 176-186
116. Hallgren J., Spillmann D., and Pejler G. Structural requirements and mechanism for heparin-induced activation of a recombinant mouse mast cell tryptase, mouse mast cell protease-6: Formation of active tryptase monomers in the presence of low molecular weight heparin. J. Biol. Chem. 276 (2001) 42774-42781
117. Hartmann K., and Henz B.M. Cutaneous mastocytosis-clinical heterogeneity. Int. Arch. Allergy Immunol. 127 (2002) 143-146
118. Hauswirth A.W., Simonitsch-Klupp I., Uffmann M., Koller E., Sperr W.R., Lechner K., and Valent P. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk. Res. 28 (2004) 249-257
119. Hauswirth A.W., Sperr W.R., Ghannadan M., Schernthaner G.H., Jordan J.H., Fritsche-Polanz R., Simonitsch-Klupp I., Fodinger M., Lechner K., and Valent P. A case of smoldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk. Res. 26 (2002) 601-606
120. Hehlmann R., Heimpel H., Hasford J., Kolb H.J., Pralle H., Hossfeld D.K., Queisser W., Loffler H., Hochhaus A., and Heinze B. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84 (1994) 4064-4077
121. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D., Fletcher C.D., and Fletcher J.A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
122. Hendrie P.C., Miyazawa K., Yang Y.C., Langefeld C.D., and Broxmeyer H.E. Mast cell growth factor (c-Kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e. Exp. Hematol. 19 (1991) 1031-1037
123. Hennessy B., Giles F., Cortes J., O'brien S., Ferrajoli A., Ossa G., Garcia-Manero G., Faderl S., Kantarjian H., and Verstovsek S. Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience. Am. J. Hematol. 77 (2004) 209-214
124. Herbst R., Shearman M.S., Jallal B., Schlessinger J., and Ullrich A. Formation of signal transfer complexes between stem cell and platelet-derived growth factor receptors and SH2 domain proteins in vitro. Biochemistry 34 (1995) 5971-5979
125. Hodgkinson C.A., Moore K.J., Nakayama A., Steingrimsson E., Copeland N.G., Jenkins N.A., and Arnheiter H. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74 (1993) 395-404
126. Holgate S.T., Bradding P., and Sampson A.P. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy. J. Allergy Clin. Immunol. 98 (1996) 1-13
127. Hong L., Munugalavadla V., and Kapur R. c-Kit-mediated overlapping and unique functional and biochemical outcomes via diverse signaling pathways. Mol. Cell Biol. 24 (2004) 1401-1410
128. Hongyo T., Li T., Syaifudin M., Baskar R., Ikeda H., Kanakura Y., Aozasa K., and Nomura T. Specific c-Kit mutations in sinonasal natural killer/T cell lymphoma in China and Japan. Cancer Res. 60 (2000) 2345-2347
129. Horan R.F., and Austen K.F. Systemic mastocytosis: Retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J. Invest. Dermatol. 96 (1991) 5S-13S
130. Horan R.F., Sheffer A.L., and Austen K.F. Cromolyn sodium in the management of systemic mastocytosis. J. Allergy Clin. Immunol. 85 (1990) 852-855
131. Horiuchi T., and Weller P.F. Expression of vascular endothelial growth factor by human eosinophils: Upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am. J. Respir. Cell Mol. Biol. 17 (1997) 70-77
132. Horny H.P., and Kaiserling E. Lymphoid cells and tissue mast cells of bone marrow lesions in systemic mastocytosis: A histological and immunohistological study. Br. J. Haematol. 69 (1988) 449-455
133. Horny H.P., Kaiserling E., Campbell M., Parwaresch M.R., and Lennert K. Liver findings in generalized mastocytosis. A clinicopathologic study. Cancer 63 (1989) 532-538
134. Horny H.P., Kaiserling E., Parwaresch M.R., and Lennert K. Lymph node findings in generalized mastocytosis. Histopathology 21 (1992) 439-446
135. Horny H.P., Kaiserling E., Sillaber C., Walchshofer S., and Valent P. Bone marrow mastocytosis associated with an undifferentiated extramedullary tumor of hemopoietic origin. Arch. Pathol. Lab Med. 121 (1997) 423-426
136. Horny H.P., Parwaresch M.R., Kaiserling E., Muller K., Olbermann M., Mainzer K., and Lennert K. Mast cell sarcoma of the larynx. J. Clin. Pathol. 39 (1986) 596-602
137. Horny H.P., Ruck M., Wehrmann M., and Kaiserling E. Blood findings in generalized mastocytosis: Evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br. J. Haematol. 76 (1990) 186-193
138. Horny H.P., Ruck M.T., and Kaiserling E. Spleen findings in generalized mastocytosis. A clinicopathologic study. Cancer 70 (1992) 459-468
139. Horny H.P., Sillaber C., Menke D., Kaiserling E., Wehrmann M., Stehberger B., Chott A., Lechner K., Lennert K., and Valent P. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am. J. Surg. Pathol. 22 (1998) 1132-1140
140. Horny H.P., Sotlar K., Sperr W.R., and Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: A histopathological challenge. J. Clin. Pathol. 57 (2004) 604-608
141. Horny H.P., and Valent P. Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk. Res. 25 (2001) 543-551
142. Horny H.P., and Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int. Arch. Allergy Immunol. 127 (2002) 115-117
143. Hoshida Y., Hongyo T., Jia X., He Y., Hasui K., Dong Z., Luo W.J., Ham M.F., Nomura T., and Aozasa K. Analysis of p53, K-ras, c-Kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China. Cancer Sci. 94 (2003) 297-301
144. Huber M., Helgason C.D., Damen J.E., Liu L., Humphries R.K., and Krystal G. The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc. Natl. Acad. Sci. USA 95 (1998) 11330-11335
145. Huber M., Helgason C.D., Scheid M.P., Duronio V., Humphries R.K., and Krystal G. Targeted disruption of SHIP leads to Steel factor-induced degranulation of mast cells. EMBO J. 17 (1998) 7311-7319
146. Hubner C., Wedding U., Strater J., Limberg B., and Stremmel W. Clinical stable systemic mastocytosis with interferon alpha-2b therapy. J. Intern. Med. 241 (1997) 529-533
147. Iemura A., Tsai M., Ando A., Wershil B.K., and Galli S.J. The c-Kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am. J. Pathol. 144 (1994) 321-328
148. Ihle J.N., Keller J., Oroszlan S., Henderson L.E., Copeland T.D., Fitch F., Prystowsky M.B., Goldwasser E., Schrader J.W., Palaszynski E., Dy M., and Lebel B. Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J. Immunol. 131 (1983) 282-287
149. Iijima K., Yoshikawa N., and Nakamura H. Activation-induced expression of vascular permeability factor by human peripheral T cells: A non-radioisotopic semiquantitative reverse transcription-polymerase chain reaction assay. J. Immunol. Methods 196 (1996) 199-209
150. Irani A.M., Nilsson G., Miettinen U., Craig S.S., Ashman L.K., Ishizaka T., Zsebo K.M., and Schwartz L.B. Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 80 (1992) 3009-3021
151. Isersky C., Rivera J., Mims S., and Triche T.J. The fate of IgE bound to rat basophilic leukemia cells. J. Immunol. 122 (1979) 1926-1936
152. Jacobs-Helber S.M., Penta K., Sun Z., Lawson A., and Sawyer S.T. Distinct signaling from stem cell factor and erythropoietin in HCD57 cells. J. Biol. Chem. 272 (1997) 6850-6853
153. Jahn T., Seipel P., Coutinho S., Urschel S., Schwarz K., Miething C., Serve H., Peschel C., and Duyster J. Analysing c-Kit internalization using a functional c-Kit-EGFP chimera containing the fluorochrome within the extracellular domain. Oncogene 21 (2002) 4508-4520
154. Janowska-Wieczorek A., Majka M., Ratajczak J., and Ratajczak M.Z. Autocrine/paracrine mechanisms in human hematopoiesis. Stem Cells 19 (2001) 99-107
155. Jensen R.T. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol. Oncol. Clin. North Am. 14 (2000) 579-623
156. Jiang J., Paez J.G., Lee J.C., Bo R., Stone R.M., De Angelo D.J., Galinsky I., Wolpin B.M., Jonasova A., Herman P., Fox E.A., Boggon T.J., Eck M.J., Weisberg E., Griffin J.D., Gilliland D.G., Meyerson M., and Sellers W.R. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 104 (2004) 1855-1858
157. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., Boyce B., Broxmeyer H., and Manolagas S.C. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257 (1992) 88-91
158. Joensuu H., and Kindblom L.G. Gastrointestinal stromal tumors-a review. Acta Orthop. Scand. Suppl. 75 (2004) 62-71
159. Joneja B., Chen H.C., Seshasayee D., Wrentmore A.L., and Wojchowski D.M. Mechanisms of stem cell factor and erythropoietin proliferative co-signaling in FDC2-ER cells. Blood 90 (1997) 3533-3545
160. Jordan J.H., Fritsche-Polanz R., Sperr W.R., Mitterbauer G., Fodinger M., Schernthaner G.H., Christian B.H., Gebhart W., Chott A., Lechner K., and Valent P. A case of 'smoldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk. Res. 25 (2001) 627-634
161. Joris I., Majno G., Corey E.J., and Lewis R.A. The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. Am. J. Pathol. 126 (1987) 19-24
162. Jutel M., Watanabe T., Klunker S., Akdis M., Thomet O.A., Malolepszy J., Zak-Nejmark T., Koga R., Kobayashi T., Blaser K., and Akdis C.A. Histamine regulates T cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413 (2001) 420-425
163. Kambe M., Kambe N., Oskeritzian C.A., Schechter N., and Schwartz L.B. IL-6 attenuates apoptosis, while neither IL-6 nor IL-10 affect the numbers or protease phenotype of fetal liver-derived human mast cells. Clin. Exp. Allergy 31 (2001) 1077-1085
164. Kanakura Y., Furitsu T., Tsujimura T., Butterfield J.H., Ashman L.K., Ikeda H., Kitayama H., Kanayama Y., Matsuzawa Y., and Kitamura Y. Activating mutations of the c-Kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 8 Suppl. 1 (1994) S18-S22
165. Katz H.R., Arm J.P., Benson A.C., and Austen K.F. Maturation-related changes in the expression of Fc gamma RII and Fc gamma RIII on mouse mast cells derived in vitro and in vivo. J. Immunol. 145 (1990) 3412-3417
166. Kelly L.M., and Gilliland D.G. Genetics of myeloid leukemias. Annu. Rev. Genomics Hum. Genet. 3 (2002) 179-198
167. Kelly L.M., Liu Q., Kutok J.L., Williams I.R., Boulton C.L., and Gilliland D.G. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99 (2002) 310-318
168. Kemmer K., Corless C.L., Fletcher J.A., McGreevey L., Haley A., Griffith D., Cummings O.W., Wait C., Town A., and Heinrich M.C. KIT mutations are common in testicular seminomas. Am. J. Pathol. 164 (2004) 305-313
169. Keyzer J.J., De Monchy J.G., Van Doormaal J.J., and Van V. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N. Engl. J. Med. 309 (1983) 1603-1605
170. Kimura Y., Jones N., Kluppel M., Hirashima M., Tachibana K., Cohn J.B., Wrana J.L., Pawson T., and Bernstein A. Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. Proc. Natl. Acad. Sci. USA 101 (2004) 6015-6020
171. Kirshenbaum A. Regulation of mast cell number and function1. Hematol. Oncol. Clin. North Am. 14 (2000) 497-516
172. Kirshenbaum A.S., Akin C., Goff J.P., and Metcalfe D.D. Thrombopoietin alone or in the presence of stem cell factor supports the growth of KIT(CD117)low/ MPL(CD110)+ human mast cells from hematopoietic progenitor cells. Exp. Hematol. 33 (2005) 413-421
173. Kirshenbaum A.S., Akin C., Wu Y., Rottem M., Goff J.P., Beaven M.A., Rao V.K., and Metcalfe D.D. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk. Res. 27 (2003) 677-682
174. Kirshenbaum A.S., Goff J.P., Kessler S.W., Mican J.M., Zsebo K.M., and Metcalfe D.D. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J. Immunol. 148 (1992) 772-777
175. Kirshenbaum A.S., Goff J.P., Semere T., Foster B., Scott L.M., and Metcalfe D.D. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-Kit(+), and expresses aminopeptidase N (CD13). Blood 94 (1999) 2333-2342
176. Kirshenbaum A.S., Kessler S.W., Goff J.P., and Metcalfe D.D. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J. Immunol. 146 (1991) 1410-1415
177. Kissel H., Timokhina I., Hardy M.P., Rothschild G., Tajima Y., Soares V., Angeles M., Whitlow S.R., Manova K., and Besmer P. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses. EMBO J. 19 (2000) 1312-1326
178. Kitamura Y., and Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol. Life Sci. 61 (2004) 2924-2931
179. Kitamura Y., Morii E., Ogihara H., Jippo T., and Ito A. Mutant mice: A useful tool for studying the development of mast cells. Int. Arch. Allergy Immunol. 124 (2001) 16-19
180. Kitamura Y., Taguchi T., Yokoyama M., Inoue M., Yamatodani A., Asano H., Koyama T., Kanamaru A., Hatanaka K., and Wershil B.K. Higher susceptibility of masT cell-deficient W/WV mutant mice to brain thromboembolism and mortality caused by intravenous injection of India ink. Am. J. Pathol. 122 (1986) 469-480
181. Kitamura Y., Yokoyama M., Matsuda H., Ohno T., and Mori K.J. Spleen colony-forming cell as common precursor for tissue mast cells and granulocytes. Nature 291 (1981) 159-160
182. Klion A.D., Noel P., Akin C., Law M.A., Gilliland D.G., Cools J., Metcalfe D.D., and Nutman T.B. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101 (2003) 4660-4666
183. Klion A.D., Robyn J., Akin C., Noel P., Brown M., Law M., Metcalfe D.D., Dunbar C., and Nutman T.B. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103 (2004) 473-478
184. Kluin-Nelemans H.C., Jansen J.H., Breukelman H., Wolthers B.G., Kluin P.M., Kroon H.M., and Willemze R. Response to interferon alfa-2b in a patient with systemic mastocytosis. N. Engl. J. Med. 326 (1992) 619-623
185. Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., Van 't Wout J.W., Verhoef G., Gerrits W.B., van Dobbenburgh O.A., Pasmans S.G., and Fijnheer R. Cladribine therapy for systemic mastocytosis. Blood 102 (2003) 4270-4276
186. Kocabas C.N., Yavuz A.S., Lipsky P.E., Metcalfe D.D., and Akin C. Analysis of the lineage relationship between mast cells and basophils using the c-Kit D816V mutation as a biologic signature. J. Allergy Clin. Immunol. 115 (2005) 1155-1161
187. Koike T., Hirai K., Morita Y., and Nozawa Y. Stem cell factor-induced signal transduction in rat mast cells. Activation of phospholipase D but not phosphoinositide-specific phospholipase C in c-Kit receptor stimulation 2. J. Immunol. 151 (1993) 359-366
188. Kojima M., Nakamura S., Itoh H., Ohno Y., Masawa N., Joshita T., and Suchi T. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod. Pathol. 12 (1999) 739-743
189. Kolde G., Sunderkotter C., and Luger T.A. Treatment of urticaria pigmentosa using interferon alpha. Br. J. Dermatol. 133 (1995) 91-94
190. Kozawa O., Blume-Jensen P., Heldin C.H., and Ronnstrand L. Involvement of phosphatidylinositol 3′-kinase in stem-cell-factor-induced phospholipase D activation and arachidonic acid release. Eur. J. Biochem. 248 (1997) 149-155
191. Kozlowski M., Larose L., Lee F., Le D.M., Rottapel R., and Siminovitch K.A. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol. Cell Biol. 18 (1998) 2089-2099
192. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353 (2005) 172-187
193. Krystal G.W., DeBerry C.S., Linnekin D., and Litz J. Lck associates with and is activated by Kit in a small cell lung cancer cell line: Inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Cancer Res. 58 (1998) 4660-4666
194. Kudo H., Morinaga S., Shimosato Y., Noguchi M., Mizutani Y., Asamura H., and Naruke T. Solitary mast cell tumor of the lung. Cancer 61 (1988) 2089-2094
195. Kulka M., Alexopoulou L., Flavell R.A., and Metcalfe D.D. Activation of mast cells by double-stranded RNA: Evidence for activation through Toll-like receptor 3. J. Allergy Clin. Immunol. 114 (2004) 174-182
196. Kulka M., and Metcalfe D.D. High-resolution tracking of cell division demonstrates differential effects of TH1 and TH2 cytokines on SCF-dependent human mast cell production in vitro: Correlation with apoptosis and Kit expression. Blood 105 (2005) 592-599
197. Kurosawa M., Amano H., Kanbe N., Igarashi Y., Nagata H., Yamashita T., Kurimoto F., and Miyachi Y. Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis. J. Allergy Clin. Immunol. 103 (1999) S412-S420
198. Lawrence J.B., Friedman B.S., Travis W.D., Chinchilli V.M., Metcalfe D.D., and Gralnick H.R. Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis. Am. J. Med. 91 (1991) 612-624
199. Le Cam M.T., Wolkenstein P., Cosnes A., Bocquet H., Gaulard P., Tulliez M., Cordonnier C., Roujeau J.C., Bagot M., and Revuz J. Acute mast cell leukemia disclosed by vasomotor flushing. Ann. Dermatol. Venereol. 124 (1997) 621-622
200. Lee C.G., Homer R.J., Zhu Z., Lanone S., Wang X., Koteliansky V., Shipley J.M., Gotwals P., Noble P., Chen Q., Senior R.M., and Elias J.A. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J. Exp. Med. 194 (2001) 809-821
201. Lehmann T., Beyeler C., Lammle B., Hunziker T., Vock P., Olah A.J., Dahinden C., and Gerber N.J. Severe osteoporosis due to systemic mast cell disease: Successful treatment with interferon alpha-2B. Br. J. Rheumatol. 35 (1996) 898-900
202. Lennartsson J., Blume-Jensen P., Hermanson M., Ponten E., Carlberg M., and Ronnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-Kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 18 (1999) 5546-5553
203. Lennartsson J., Jelacic T., Linnekin D., and Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23 (2005) 16-43
204. Levi-Schaffer F., and Piliponsky A.M. Tryptase, a novel link between allergic inflammation and fibrosis. Trends Immunol. 24 (2003) 158-161
205. Li C.Y. Diagnosis of mastocytosis: Value of cytochemistry and immunohistochemistry. Leuk. Res. 25 (2001) 537-541
206. Li L., Meng X.W., and Krilis S.A. Mast cells expressing chymase but not tryptase can be derived by culturing human progenitors in conditioned medium obtained from a human mastocytosis cell strain with c-Kit ligand3. J. Immunol. 156 (1996) 4839-4844
207. Lindner P.S., Pardanani B., Angadi C., and Frieri M. Acute nonlymphocytic leukemia in systemic mastocytosis with biclonal gammopathy. J. Allergy Clin. Immunol. 90 (1992) 410-412
208. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int. J. Biochem. Cell Biol. 31 (1999) 1053-1074
209. Linnekin D., De Berry C.S., and Mou S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J. Biol. Chem. 272 (1997) 27450-27455
210. Liu L., Cutler R.L., Mui A.L., and Krystal G. Steel factor stimulates the serine/threonine phosphorylation of the interleukin-3 receptor. J. Biol. Chem. 269 (1994) 16774-16779
211. Liu L., Damen J.E., Cutler R.L., and Krystal G. Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc. Mol. Cell Biol. 14 (1994) 6926-6935
212. Loh M.L., Vattikuti S., Schubbert S., Reynolds M.G., Carlson E., Lieuw K.H., Cheng J.W., Lee C.M., Stokoe D., Bonifas J.M., Curtiss N.P., Gotlib J., Meshinchi S., Le Beau M.M., Emanuel P.D., and Shannon K.M. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103 (2004) 2325-2331
213. Longley Jr. B.J., Metcalfe D.D., Tharp M., Wang X., Tyrrell L., Lu S.Z., Heitjan D., and Ma Y. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. USA 96 (1999) 1609-1614
214. Longley B.J., Tyrrell L., Lu S.Z., Ma Y.S., Langley K., Ding T.G., Duffy T., Jacobs P., Tang L.H., and Modlin I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12 (1996) 312-314
215. Lorenz U., Bergemann A.D., Steinberg H.N., Flanagan J.G., Li X., Galli S.J., and Neel B.G. Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1. J. Exp. Med. 184 (1996) 1111-1126
216. Lu-Kuo J.M., Fruman D.A., Joyal D.M., Cantley L.C., and Katz H.R. Impaired kit- but not FcepsilonRI-initiated mast cell activation in the absence of phosphoinositide 3-kinase p85alpha gene products. J. Biol. Chem. 275 (2000) 6022-6029
217. Lyon M.F., and Glenister P.H. A new allele sash (Wsh) at the W-locus and a spontaneous recessive lethal in mice. Genet. Res. 39 (1982) 315-322
218. Ma Y., Cunningham M.E., Wang X., Ghosh I., Regan L., and Longley B.J. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J. Biol. Chem. 274 (1999) 13399-13402
219. Ma Y., Zeng S., Metcalfe D.D., Akin C., Dimitrijevic S., Butterfield J.H., McMahon G., and Longley B.J. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99 (2002) 1741-1744
220. MacGlashan Jr. D., Lichtenstein L.M., Kenzie-White J., Chichester K., Henry A.J., Sutton B.J., and Gould H.J. Upregulation of FcepsilonRI on human basophils by IgE antibody is mediated by interaction of IgE with FcepsilonRI. J. Allergy Clin. Immunol. 104 (1999) 492-498
221. Maddens S., Charruyer A., Plo I., Dubreuil P., Berger S., Salles B., Laurent G., and Jaffrezou J.P. Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: Implication in stem cell factor radioprotective effect. Blood 100 (2002) 1294-1301
222. Maeyama H., Hidaka E., Ota H., Minami S., Kajiyama M., Kuraishi A., Mori H., Matsuda Y., Wada S., Sodeyama H., Nakata S., Kawamura N., Hata S., Watanabe M., Iijima Y., and Katsuyama T. Familial gastrointestinal stromal tumor with hyperpigmentation: Association with a germ line mutation of the c-Kit gene. Gastroenterology 120 (2001) 210-215
223. Malaviya R., Ikeda T., Ross E., and Abraham S.N. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 381 (1996) 77-80
224. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
225. Marone G., Spadaro G., and Genovese A. Biology, diagnosis and therapy of mastocytosis. Chem. Immunol. 62 (1995) 1-21
226. Marone G., and Stellato C. Activation of human mast cells and basophils by general anaesthetic drugs. Monogr. Allergy 30 (1992) 54-73
227. Marshall J.S., and Jawdat D.M. Mast cells in innate immunity. J. Allergy Clin. Immunol. 114 (2004) 21-27
228. Matsuda H., Kannan Y., Ushio H., Kiso Y., Kanemoto T., Suzuki H., and Kitamura Y. Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J. Exp. Med. 174 (1991) 7-14
229. Maurer M., Echtenacher B., Hultner L., Kollias G., Mannel D.N., Langley K.E., and Galli S.J. The c-Kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. J. Exp. Med. 188 (1998) 2343-2348
230. McCurdy J.D., Lin T.J., and Marshall J.S. Toll-like receptor 4-mediated activation of murine mast cells. J. Leukoc. Biol. 70 (2001) 977-984
231. McCurdy J.D., Olynych T.J., Maher L.H., and Marshall J.S. Cutting edge: Distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 170 (2003) 1625-1629
232. Meggs W.J., Frieri M., Costello R., Metcalfe D.D., and Papadopoulos N.M. Oligoclonal immunoglobulins in mastocytosis. Ann. Intern. Med. 103 (1985) 894-895
233. Mekori Y.A. Lymphoid tissues and the immune system in mastocytosis. Hematol. Oncol. Clin. North Am. 14 (2000) 569-577
234. Mekori Y.A., Gilfillan A.M., Akin C., Hartmann K., and Metcalfe D.D. Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL. J. Clin. Immunol. 21 (2001) 171-174
235. Mekori Y.A., and Metcalfe D.D. Mast cell-T cell interactions. J. Allergy Clin. Immunol. 104 (1999) 517-523
236. Mekori Y.A., and Metcalfe D.D. Mast cells in innate immunity. Immunol. Rev. 173 (2000) 131-140
237. Meng H., Tonnesen M.G., Marchese M.J., Clark R.A., Bahou W.F., and Gruber B.L. Mast cells are potent regulators of endothelial cell adhesion molecule ICAM-1 and VCAM-1 expression. J. Cell Physiol. 165 (1995) 40-53
238. Metcalfe D.D. Classification and diagnosis of mastocytosis: Current status. J. Invest. Dermatol. 96 (1991) 2S-4S
239. Metcalfe D.D. The liver, spleen, and lymph nodes in mastocytosis. J. Invest. Dermatol. 96 (1991) 45S-46S
240. Metcalfe D.D., and Akin C. Mastocytosis: Molecular mechanisms and clinical disease heterogeneity. Leuk. Res. 25 (2001) 577-582
241. Metcalfe D.D., Baram D., and Mekori Y.A. Mast cells. Physiol. Rev. 77 (1997) 1033-1079
242. Mican J.M., Di Bisceglie A.M., Fong T.L., Travis W.D., Kleiner D.E., Baker B., and Metcalfe D.D. Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases. Hepatology 22 (1995) 1163-1170
243. Mirowski G., Austen K.F., Chiang L., Horan R.F., Sheffer A.L., Weidner N., and Murphy G.F. Characterization of cellular dermal infiltrates in human cutaneous mastocytosis. Lab. Invest. 63 (1990) 52-62
244. Mitsui H., Furitsu T., Dvorak A.M., Irani A.M., Schwartz L.B., Inagaki N., Takei M., Ishizaka K., Zsebo K.M., and Gillis S. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-Kit ligand. Proc. Natl. Acad. Sci. USA 90 (1993) 735-739
245. Miyazawa K., Hendrie P.C., Mantel C., Wood K., Ashman L.K., and Broxmeyer H.E. Comparative analysis of signaling pathways between mast cell growth factor (c-Kit ligand) and granulocyte-macrophage colony-stimulating factor in a human factor-dependent myeloid cell line involves phosphorylation of Raf-1, GTPase-activating protein and mitogen-activated protein kinase. Exp. Hematol. 19 (1991) 1110-1123
246. Miyazawa K., Williams D.A., Gotoh A., Nishimaki J., Broxmeyer H.E., and Toyama K. Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-Kit gene-encoded protein than its soluble form. Blood 85 (1995) 641-649
247. Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y., Sang B.C., Nowakowski J., Kassel D.B., Cronin C.N., and McRee D.E. Structure of a c-Kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 278 (2003) 31461-31464
248. Moller A., Lippert U., Lessmann D., Kolde G., Hamann K., Welker P., Schadendorf D., Rosenbach T., Luger T., and Czarnetzki B.M. Human mast cells produce IL-8. J. Immunol. 151 (1993) 3261-3266
249. Moller C., Alfredsson J., Engstrom M., Wootz H., Xiang Z., Lennartsson J., Jonsson J.I., and Nilsson G. Stem cell factor promotes mast cell survival via inactivation of FOXO3a mediated transcriptional induction and MEK regulated phosphorylation of the pro-apoptotic protein Bim. Blood 106 (2005) 1330-1336
250. Morii E., Takebayashi K., Motohashi H., Yamamoto M., Nomura S., and Kitamura Y. Loss of DNA binding ability of the transcription factor encoded by the mutant mi locus. Biochem. Biophys. Res. Commun. 205 (1994) 1299-1304
251. Morrow J.D., Minton T.A., Awad J.A., and Roberts L.J. Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans following the application of sorbic acid. Arch. Dermatol. 130 (1994) 1408-1412
252. Musto P., Falcone A., Sanpaolo G., Bodenizza C., and Carella A.M. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leuk. Res. 28 (2004) 421-422
253. Musto P., Falcone A., Sanpaolo G., Bodenizza C., Perla G., Minervini M.M., Cascavilla N., Dell'Olio M., La S.A., Mantuano S., Melillo L., Nobile M., Scalzulli P.R., Bisceglia M., and Carella A.M. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: Implications for dosing and pathogenesis. Leuk. Lymphoma 45 (2004) 1219-1222
254. Mylanus E.A., Wielinga E.W., and van de Nes J.A. A solitary manifestation of mastocytosis in the head and neck. Eur. Arch. Otorhinolaryngol. 257 (2000) 270-272
255. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., and Metcalfe D.D. Identification of a point mutation in the catalytic domain of the protooncogene c-Kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92 (1995) 10560-10564
256. Nakano T., Kanakura Y., Nakahata T., Matsuda H., and Kitamura Y. Genetically mast cell-deficient W/Wv mice as a tool for studies of differentiation and function of mast cells. Fed. Proc. 46 (1987) 1920-1923
257. Nakata Y., Kimura A., Katoh O., Kawaishi K., Hyodo H., Abe K., Kuramoto A., and Satow Y. c-Kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br. J. Haematol. 91 (1995) 661-663
258. Nettleship P. Rare forms of urticaria. Br. Med. J. 2 (1869) 323
259. Nilsson G., Butterfield J.H., Nilsson K., and Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J. Immunol. 153 (1994) 3717-3723
260. Nilsson G., Miettinen U., Ishizaka T., Ashman L.K., Irani A.M., and Schwartz L.B. Interleukin-4 inhibits the expression of Kit and tryptase during stem cell factor-dependent development of human mast cells from fetal liver cells. Blood 84 (1994) 1519-1527
261. Noack F., Sotlar K., Notter M., Thiel E., Valent P., and Horny H.P. Aleukemic mast cell leukemia with abnormal immunophenotype and c-Kit mutation D816V. Leuk. Lymphoma 45 (2004) 2295-2302
262. Norrby K. Mast cells and de novo angiogenesis: Angiogenic capability of individual masT cell mediators such as histamine, TNF, IL-8 and bFGF. Inflamm. Res. 46 Suppl. 1 (1997) S7-S8
263. Nugent M.A., and Iozzo R.V. Fibroblast growth factor-2. Int. J. Biochem. Cell Biol. 32 (2000) 115-120
264. O'Farrell A.M., Ichihara M., Mui A.L., and Miyajima A. Signaling pathways activated in a unique mast cell line where interleukin-3 supports survival and stem cell factor is required for a proliferative response. Blood 87 (1996) 3655-3668
265. O'Hare T., Walters D.K., Deininger M.W., and Druker B.J. AMN107: Tightening the grip of imatinib. Cancer Cell 7 (2005) 117-119
266. O'Laughlin-Bunner B., Radosevic N., Taylor M.L., Shivakrupa, DeBerry C., Metcalfe D.D., Zhou M., Lowell C., and Linnekin D. Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood 98 (2001) 343-350
267. Oettgen H.C., Martin T.R., Wynshaw-Boris A., Deng C., Drazen J.M., and Leder P. Active anaphylaxis in IgE-deficient mice. Nature 370 (1994) 367-370
268. Ohnishi K., Ohno R., Tomonaga M., Kamada N., Onozawa K., Kuramoto A., Dohy H., Mizoguchi H., Miyawaki S., and Tsubaki K. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86 (1995) 906-916
269. Ohnishi K., Tomonaga M., Kamada N., Onozawa K., Kuramoto A., Dohy H., Mizoguchi H., Miyawaki S., Tsubaki K., Miura Y., Omine M., Kobayashi T., Naoe T., Ohshima T., Hirashima K., Ohtake S., Takahashi I., Morishima Y., Naito K., Asou N., Tanimoto M., Sakuma A., and Ohno R. A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group. Leuk. Res. 22 (1998) 779-786
270. Okayama Y., Hagaman D.D., and Metcalfe D.D. A comparison of mediators released or generated by IFN-gamma-treated human mast cells following aggregation of Fc gamma RI or Fc epsilon RI. J. Immunol. 166 (2001) 4705-4712
271. Okayama Y., Kirshenbaum A.S., and Metcalfe D.D. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: Upregulation by IFN-gamma. J. Immunol. 164 (2000) 4332-4339
272. Oskeritzian C.A., Wang Z., Kochan J.P., Grimes M., Du Z., Chang H.W., Grant S., and Schwartz L.B. Recombinant human (rh)IL-4-mediated apoptosis and recombinant human IL-6-mediated protection of recombinant human stem cell factor-dependent human mast cells derived from cord blood mononuclear cell progenitors. J. Immunol. 163 (1999) 5105-5115
273. Pardanani A., Elliott M., Reeder T., Li C.Y., Baxter E.J., Cross N.C., and Tefferi A. Imatinib for systemic masT cell disease. Lancet 362 (2003) 535-536
274. Pardanani A., Hoffbrand A.V., Butterfield J.H., and Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk. Res. 28 (2004) 127-131
275. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., Paternoster S.F., Shearer B.M., Reeder T.L., Li C.Y., Cross N.C., Cools J., Gilliland D.G., Dewald G.W., and Tefferi A. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102 (2003) 3093-3096
276. Pardanani A., Kimlinger T., Reeder T., Li C.Y., and Tefferi A. Bone marrow mast cell immunophenotyping in adults with mast cell disease: A prospective study of 33 patients. Leuk. Res. 28 (2004) 777-783
277. Parker R.I. Hematologic aspects of systemic mastocytosis. Hematol. Oncol. Clin. North Am. 14 (2000) 557-568
278. Pauls J.D., Brems J., Pockros P.J., Saven A., Wagner R.L., Weber R., Metcalfe D., and Christiansen S.C. Mastocytosis: Diverse presentations and outcomes. Arch. Intern. Med. 159 (1999) 401-405
279. Paulson R.F., Vesely S., Siminovitch K.A., and Bernstein A. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Nat. Genet. 13 (1996) 309-315
280. Pawankar R., Okuda M., Yssel H., Okumura K., and Ra C. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J. Clin. Invest. 99 (1997) 1492-1499
281. Payne V., and Kam P.C. Mast cell tryptase: A review of its physiology and clinical significance. Anaesthesia 59 (2004) 695-703
282. Pejler G., and Karlstrom A. Thrombin is inactivated by mast cell secretory granule chymase. J. Biol. Chem. 268 (1993) 11817-11822
283. Penrose J.F., Gagnon L., Goppelt-Struebe M., Myers P., Lam B.K., Jack R.M., Austen K.F., and Soberman R.J. Purification of human leukotriene C4 synthase. Proc. Natl. Acad. Sci. USA 89 (1992) 11603-11606
284. Perez-Ruiz M., Ros J., Morales-Ruiz M., Navasa M., Colmenero J., Ruiz-del-Arbol L., Cejudo P., Claria J., Rivera F., Arroyo V., Rodes J., and Jimenez W. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: Regulation by cytokines and bacterial lipopolysaccharide. Hepatology 29 (1999) 1057-1063
285. Pignon J.M., Giraudier S., Duquesnoy P., Jouault H., Imbert M., Vainchenker W., Vernant J.P., and Tulliez M. A new c-Kit mutation in a case of aggressive mast cell disease. Br. J. Haematol. 96 (1997) 374-376
286. Plo I., Lautier D., Casteran N., Dubreuil P., Arock M., and Laurent G. Kit signaling and negative regulation of daunorubicin-induced apoptosis: Role of phospholipase Cgamma. Oncogene 20 (2001) 6752-6763
287. Prodeus A.P., Zhou X., Maurer M., Galli S.J., and Carroll M.C. Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 390 (1997) 172-175
288. Przepiorka D., Giralt S., Khouri I., Champlin R., and Bueso-Ramos C. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: Review of forty cases1. Am. J. Hematol. 57 (1998) 24-28
289. Pulik M., Lionnet F., Petit A., Genet P., and Gaulier A. Long-term response to interferon-alpha in a patient with systemic mastocytosis and chronic myelomonocytic leukemia. Am. J. Hematol. 47 (1994) 66
290. Puxeddu I., Piliponsky A.M., Bachelet I., and Levi-Schaffer F. Mast cells in allergy and beyond. Int. J. Biochem. Cell Biol. 35 (2003) 1601-1607
291. Qu Z., Huang X., Ahmadi P., Stenberg P., Liebler J.M., Le A.C., Planck S.R., and Rosenbaum J.T. Synthesis of basic fibroblast growth factor by murine mast cells. Regulation by transforming growth factor beta, tumor necrosis factor alpha, and stem cell factor. Int. Arch. Allergy Immunol. 115 (1998) 47-54
292. Qu Z., Kayton R.J., Ahmadi P., Liebler J.M., Powers M.R., Planck S.R., and Rosenbaum J.T. Ultrastructural immunolocalization of basic fibroblast growth factor in mast cell secretory granules. Morphological evidence for bfgf release through degranulation. J. Histochem. Cytochem. 46 (1998) 1119-1128
293. Radosevic N., Winterstein D., Keller J.R., Neubauer H., Pfeffer K., and Linnekin D. JAK2 contributes to the intrinsic capacity of primary hematopoietic cells to respond to stem cell factor. Exp. Hematol. 32 (2004) 149-156
294. Rafii M., Firooznia H., Golimbu C., and Balthazar E. Pathologic fracture in systemic mastocytosis. Radiographic spectrum and review of the literature. Clin. Orthop. Relat Res., (1983) 260-267
295. Ribatti D., Crivellato E., Candussio L., Nico B., Vacca A., Roncali L., and Dammacco F. Mast cells and their secretory granules are angiogenic in the chick embryo chorioallantoic membrane1. Clin. Exp. Allergy 31 (2001) 602-608
296. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
297. Robson M.E., Glogowski E., Sommer G., Antonescu C.R., Nafa K., Maki R.G., Ellis N., Besmer P., Brennan M., and Offit K. Pleomorphic characteristics of a germ line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin. Cancer Res. 10 (2004) 1250-1254
298. Ronnov-Jessen D., Lovgreen N.P., and Horn T. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant. 8 (1991) 413-415
299. Rottapel R., Reedijk M., Williams D.E., Lyman S.D., Anderson D.M., Pawson T., and Bernstein A. The Steel/W transduction pathway: Kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. Mol. Cell. Biol. 11 (1991) 3043-3051
300. Rottem M., Hull G., and Metcalfe D.D. Demonstration of differential effects of cytokines on mast cells derived from murine bone marrow and peripheral blood mononuclear cells. Exp. Hematol. 22 (1994) 1147-1155
301. Rottem M., Okada T., Goff J.P., and Metcalfe D.D. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fc epsilon RI- cell population. Blood 84 (1994) 2489-2496
302. Rumsaeng V., Cruikshank W.W., Foster B., Prussin C., Kirshenbaum A.S., Davis T.A., Kornfeld H., Center D.M., and Metcalfe D.D. Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J. Immunol. 159 (1997) 2904-2910
303. Ryan J.J., Huang H., McReynolds L.J., Shelburne C., Hu-Li J., Huff T.F., and Paul W.E. Stem cell factor activates STAT-5 DNA binding in IL-3-derived bone marrow mast cells. Exp. Hematol. 25 (1997) 357-362
304. Sakuma Y., Sakurai S., Oguni S., Hironaka M., and Saito K. Alterations of the c-Kit gene in testicular germ cell tumors. Cancer Sci. 94 (2003) 486-491
305. Samoszuk M., Corwin M., and Hazen S.L. Effects of human mast cell tryptase on the kinetics of blood clotting. Thromb. Res. 109 (2003) 153-156
306. Sattler M., and Salgia R. Targeting c-Kit mutations: Basic science to novel therapies. Leuk. Res. 28 Suppl. 1 (2004) S11-S20
307. Sawyers C.L.S.N.P., Kantarjain H.M., Donato N., Nicoll J., Bai S.A., Huang F., Clark E., De Cillis A.P., and Talpaz M. Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC//ABL kinase inhibitor. Blood 104 (2004) 1a
308. Schwartz L.B. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk. Res. 25 (2001) 553-562
309. Schwartz L.B., Bradford T.R., Littman B.H., and Wintroub B.U. The fibrinogenolytic activity of purified tryptase from human lung mast cells. J. Immunol. 135 (1985) 2762-2767
310. Schwartz L.B., and Irani A.M. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol. Oncol. Clin. North Am. 14 (2000) 641-657
311. Schwartz L.B., Min H.K., Ren S., Xia H.Z., Hu J., Zhao W., Moxley G., and Fukuoka Y. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J. Immunol. 170 (2003) 5667-5673
312. Schwartz L.B., Sakai K., Bradford T.R., Ren S., Zweiman B., Worobec A.S., and Metcalfe D.D. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J. Clin. Invest. 96 (1995) 2702-2710
313. Scott Jr. H.W., Parris W.C., Sandidge P.C., Oates J.A., and Roberts L.J. Hazards in operative management of patients with systemic mastocytosis. Ann. Surg. 197 (1983) 507-514
314. Sezary A., and Chauvillon P. Dermographisme et mastocytose. Bull. Soc. Fr. Dermatol. Syph. 43 (1936) 359-361
315. Shah N.P., Lee F.Y., Sawyers C.L., and Akin C. BMS-354825 is a SRC/ABL inhibitor with high nanomolar activity against the Kit D816V mutation which drives systemic mastocytosis and is imatinib-resistant. Blood 104 (2004) 228a
316. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
317. Shultz L.D., Schweitzer P.A., Rajan T.V., Yi T., Ihle J.N., Matthews R.J., Thomas M.L., and Beier D.R. Mutations at the murine moth-eaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73 (1993) 1445-1454
318. Sillaber C., Baghestanian M., Bevec D., Willheim M., Agis H., Kapiotis S., Fureder W., Bankl H.C., Kiener H.P., Speiser W., Binder B.R., Lechner K., and Valent P. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J. Immunol. 162 (1999) 1032-1041
319. Simon J., Lortholary O., Caillat-Vigneron N., Raphael M., Martin A., Briere J., Barete S., Hermine O., and Casassus P. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol. Biol. (Paris) 52 (2004) 294-299
320. Smith C.A., and Rennick D.M. Characterization of a murine lymphokine distinct from interleukin 2 and interleukin 3 (IL-3) possessing a T cell growth factor activity and a masT cell growth factor activity that synergizes with IL-3. Proc. Natl. Acad. Sci. USA 83 (1986) 1857-1861
321. Smith G.B., Gusberg R.J., Jordan R.H., and Kim B. Histamine levels and cardiovascular responses during splenectomy and splenorenal shunt formation in a patient with systemic mastocytosis. Anaesthesia 42 (1987) 861-867
322. Smith T.F., Welch T.R., Allen J.B., and Sondheimer J.M. Cutaneous mastocytosis with bleeding: Probable heparin effect. Cutis 39 (1987) 241-244
323. Soter N.A., Austen K.F., and Wasserman S.I. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N. Engl. J. Med. 301 (1979) 465-469
324. Soto D., Malmsten C., Blount J.L., Muilenburg D.J., and Caughey G.H. Genetic deficiency of human mast cell alpha-tryptase. Clin. Exp. Allergy 32 (2002) 1000-1006
325. Sperr W.R., Czerwenka K., Mundigler G., Muller M.R., Semper H., Klappacher G., Glogar H.D., Lechner K., and Valent P. Specific activation of human mast cells by the ligand for c-Kit: Comparison between lung, uterus and heart mast cells235. Int. Arch. Allergy Immunol. 102 (1993) 170-175
326. Sperr W.R., Escribano L., Jordan J.H., Schernthaner G.H., Kundi M., Horny H.P., and Valent P. Morphologic properties of neoplastic mast cells: Delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 25 (2001) 529-536
327. Sperr W.R., Horny H.P., Lechner K., and Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk. Lymphoma 37 (2000) 473-486
328. Sperr W.R., Horny H.P., and Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int. Arch. Allergy Immunol. 127 (2002) 140-142
329. Sperr W.R., Jordan J.H., Baghestanian M., Kiener H.P., Samorapoompichit P., Semper H., Hauswirth A., Schernthaner G.H., Chott A., Natter S., Kraft D., Valenta R., Schwartz L.B., Geissler K., Lechner K., and Valent P. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 98 (2001) 2200-2209
330. Sperr W.R., Jordan J.H., Fiegl M., Escribano L., Bellas C., Dirnhofer S., Semper H., Simonitsch-Klupp I., Horny H.P., and Valent P. Serum tryptase levels in patients with mastocytosis: Correlation with mast cell burden and implication for defining the category of disease. Int. Arch. Allergy Immunol. 128 (2002) 136-141
331. Sperr W.R., Stehberger B., Wimazal F., Baghestanian M., Schwartz L.B., Kundi M., Semper H., Jordan J.H., Chott A., Drach J., Jager U., Geissler K., Greschniok A., Horny H.P., Lechner K., and Valent P. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk. Lymphoma 43 (2002) 1097-1105
332. Sperr W.R., Walchshofer S., Horny H.P., Fodinger M., Simonitsch I., Fritsche-Polanz R., Schwarzinger I., Tschachler E., Sillaber C., Hagen W., Geissler K., Chott A., Lechner K., and Valent P. Systemic mastocytosis associated with acute myeloid leukaemia: Report of two cases and detection of the c-Kit mutation Asp-816 to Val. Br. J. Haematol. 103 (1998) 740-749
333. Spritz R.A. Molecular basis of human piebaldism. J. Invest. Dermatol. 103 (1994) 137S-140S
334. Spyridonidis A., Thomas A.K., Bertz H., Zeiser R., Schmitt-Graff A., Lindemann A., Waller C.F., and Finke J. Evidence for a graft-versus-masT cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant. 34 (2004) 515-519
335. Stack M.S., and Johnson D.A. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J. Biol. Chem. 269 (1994) 9416-9419
336. Stellato C., de P.A., Cirillo R., Mastronardi P., Mazzarella B., and Marone G. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 74 (1991) 1078-1086
337. Stellato C., and Marone G. Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Chem. Immunol. 62 (1995) 108-131
338. Supajatura V., Ushio H., Nakao A., Akira S., Okumura K., Ra C., and Ogawa H. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J. Clin. Invest 109 (2002) 1351-1359
339. Supajatura V., Ushio H., Nakao A., Okumura K., Ra C., and Ogawa H. Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J. Immunol. 167 (2001) 2250-2256
340. Tan B.L., Yazicioglu M.N., Ingram D., McCarthy J., Borneo J., Williams D.A., and Kapur R. Genetic evidence for convergence of c-Kit- and alpha4 integrin-mediated signals on class IA PI-3kinase and the Rac pathway in regulating integrin-directed migration in mast cells. Blood 101 (2003) 4725-4732
341. Tanaka A., Konno M., Muto S., Kambe N., Morii E., Nakahata T., Itai A., and Matsuda H. A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-Kit receptors. Blood 105 (2005) 2324-2331
342. Tartaglia M., Mehler E.L., Goldberg R., Zampino G., Brunner H.G., Kremer H., van d.B., Crosby A.H., Ion A., Jeffery S., Kalidas K., Patton M.A., Kucherlapati R.S., and Gelb B.D. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29 (2001) 465-468
343. Tartaglia M., Niemeyer C.M., Fragale A., Song X., Buechner J., Jung A., Hahlen K., Hasle H., Licht J.D., and Gelb B.D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 34 (2003) 148-150
344. Tauchi T., Feng G.S., Marshall M.S., Shen R., Mantel C., Pawson T., and Broxmeyer H.E. The ubiquitously expressed Syp phosphatase interacts with c-Kit and Grb2 in hematopoietic cells. J. Biol. Chem. 269 (1994) 25206-25211
345. Taylor M.L., Dastych J., Sehgal D., Sundstrom M., Nilsson G., Akin C., Mage R.G., and Metcalfe D.D. The Kit-activating mutation D816V enhances stem cell factor-dependent chemotaxis 59. Blood 98 (2001) 1195-1199
346. Taylor M.L., Sehgal D., Raffeld M., Obiakor H., Akin C., Mage R.G., and Metcalfe D.D. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J. Mol. Diagn 6 (2004) 335-342
347. Tefferi A., Li C.Y., Butterfield J.H., and Hoagland H.C. Treatment of systemic masT cell disease with cladribine. N. Engl. J. Med. 344 (2001) 307-309
348. Temkin V., Kantor B., Weg V., Hartman M.L., and Levi-Schaffer F. Tryptase activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J. Immunol. 169 (2002) 2662-2669
349. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330 (1994) 820-825
350. Theoharides T.C., Boucher W., and Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int. Arch. Allergy Immunol. 128 (2002) 344-350
351. Tian Q., Frierson Jr. H.F., Krystal G.W., and Moskaluk C.A. Activating c-Kit gene mutations in human germ cell tumors. Am. J. Pathol. 154 (1999) 1643-1647
352. tires-Alj M., Paez J.G., David F.S., Keilhack H., Halmos B., Naoki K., Maris J.M., Richardson A., Bardelli A., Sugarbaker D.J., Richards W.G., Du J., Girard L., Minna J.D., Loh M.L., Fisher D.E., Velculescu V.E., Vogelstein B., Meyerson M., Sellers W.R., and Neel B.G. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 64 (2004) 8816-8820
353. Tkaczyk C., Okayama Y., Metcalfe D.D., and Gilfillan A.M. Fcgamma receptors on mast cells: Activatory and inhibitory regulation of mediator release. Int. Arch. Allergy Immunol. 133 (2004) 305-315
354. Tkaczyk C., Okayama Y., Woolhiser M.R., Hagaman D.D., Gilfillan A.M., and Metcalfe D.D. Activation of human mast cells through the high affinity IgG receptor. Mol. Immunol. 38 (2002) 1289-1293
355. Torrey E., Simpson K., Wilbur S., Munoz P., and Skikne B. Malignant mastocytosis with circulating mast cells. Am. J. Hematol. 34 (1990) 283-286
356. Travis W.D., Li C.Y., Bergstralh E.J., Yam L.T., and Swee R.G. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67 (1988) 345-368
357. Travis W.D., Li C.Y., Hoagland H.C., Travis L.B., and Banks P.M. Mast cell leukemia: Report of a case and review of the literature. Mayo Clin. Proc. 61 (1986) 957-966
358. Travis W.D., Li C.Y., Yam L.T., Bergstralh E.J., and Swee R.G. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 62 (1988) 965-972
359. Trevisan G., Pauluzzi P., Gatti A., and Semeraro A. Familial mastocytosis associated with neurosensory deafness. J. Eur. Acad. Dermatol. Venereol. 14 (2000) 119-122
360. Trieselmann N.Z., Soboloff J., and Berger S.A. Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation. Cell Mol. Life Sci. 60 (2003) 759-766
361. Unna P.G. Beitrage zur anatomic und pathogenese der urticaria simplex und pigmentosa. Mschr Prakt Dermatol, Suppl Dermatol Stud 3 (1887)
362. Valent P. Biology, classification and treatment of human mastocytosis. Wien. Klin. Wochenschr. 108 (1996) 385-397
363. Valent P., Akin C., Sperr W.R., Escribano L., Arock M., Horny H.P., Bennett J.M., and Metcalfe D.D. Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria. Leuk. Res. 27 (2003) 635-641
364. Valent P., Akin C., Sperr W.R., Horny H.P., Arock M., Lechner K., Bennett J.M., and Metcalfe D.D. Diagnosis and treatment of systemic mastocytosis: State of the art. Br. J. Haematol. 122 (2003) 695-717
365. Valent P., Akin C., Sperr W.R., Horny H.P., and Metcalfe D.D. Smoldering mastocytosis: A novel subtype of systemic mastocytosis with slow progression. Int. Arch. Allergy Immunol. 127 (2002) 137-139
366. Valent P., Akin C., Sperr W.R., Mayerhofer M., Fodinger M., Fritsche-Polanz R., Sotlar K., Escribano L., Arock M., Horny H.P., and Metcalfe D.D. Mastocytosis: Pathology, genetics, and current options for therapy. Leuk. Lymphoma 46 (2005) 35-48
367. Valent P., Escribano L., Parwaresch R.M., Schemmel V., Schwartz L.B., Sotlar K., Sperr W.R., and Horny H.P. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. Int. Arch. Allergy Immunol. 120 (1999) 1-7
368. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., Marone G., Nunez R., Akin C., Sotlar K., Sperr W.R., Wolff K., Brunning R.D., Parwaresch R.M., Austen K.F., Lennert K., Metcalfe D.D., Vardiman J.W., and Bennett J.M. Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk. Res. 25 (2001) 603-625
369. Valent P., Horny H.P., Li C.Y., Longley B.J., Metcalfe D.D., Parwaresch R.M., and Bennett J.M. Mastocytosis. In: Jaffe E., Harris N.L., Stein H., and Wardiman J.W. (Eds). "World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues" (2001), IARC Press, Lyon 291-302
370. Valent P., Spanblochl E., Sperr W.R., Sillaber C., Zsebo K.M., Agis H., Strobl H., Geissler K., Bettelheim P., and Lechner K. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80 (1992) 2237-2245
371. Valent P., Sperr W.R., Samorapoompichit P., Geissler K., Lechner K., Horny H.P., and Bennett J.M. Myelomastocytic overlap syndromes: Biology, criteria, and relationship to mastocytosis. Leuk. Res. 25 (2001) 595-602
372. Varadaradjalou S., Feger F., Thieblemont N., Hamouda N.B., Pleau J.M., Dy M., and Arock M. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur. J. Immunol. 33 (2003) 899-906
373. Vaughan S.T., and Jones G.N. Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia. Anaesthesia 53 (1998) 804-807
374. Walls A.F., Bennett A.R., McBride H.M., Glennie M.J., Holgate S.T., and Church M.K. Production and characterization of monoclonal antibodies specific for human mast cell tryptase. Clin. Exp. Allergy 20 (1990) 581-589
375. Walton J. Mastocytosis/vasodilatory shock in a 25-year-old woman. J. Emerg. Nurs. 15 (1989) 356-357
376. Webb T.A., Li C.Y., and Yam L.T. Systemic mast cell disease: A clinical and hematopathologic study of 26 cases. Cancer 49 (1982) 927-938
377. Weide R., Ehlenz K., Lorenz W., Walthers E., Klausmann M., and Pfluger K.H. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann. Hematol. 72 (1996) 41-43
378. Weiler S.R., Mou S., De Berry C.S., Keller J.R., Ruscetti F.W., Ferris D.K., Longo D.L., and Linnekin D. JAK2 is associated with the c-Kit proto-oncogene product and is phosphorylated in response to stem cell factor. Blood 87 (1996) 3688-3693
379. Wershil B.K., Furuta G.T., Wang Z.S., and Galli S.J. Mast cell-dependent neutrophil and mononuclear cell recruitment in immunoglobulin E-induced gastric reactions in mice. Gastroenterology 110 (1996) 1482-1490
380. Wershil B.K., Wang Z.S., Gordon J.R., and Galli S.J. Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor-alpha. J. Clin. Invest. 87 (1991) 446-453
381. Wiesner S.M., Jones J.M., Hasz D.E., and Largaespada D.A. A repressible transgenic model of NRAS oncogene driven mast cell disease in the mouse. Blood 106 (2005) 1054-1062
382. Wimazal F., Jordan J.H., Sperr W.R., Chott A., Dabbass S., Lechner K., Horny H.P., and Valent P. Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am. J. Pathol. 160 (2002) 1639-1645
383. Wolff K., Komar M., and Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk. Res. 25 (2001) 519-528
384. Worobec A.S. Treatment of systemic mast cell disorders. Hematol. Oncol. Clin. North Am. 14 (2000) 659-687 vii.
385. Worobec A.S., Akin C., Scott L.M., and Metcalfe D.D. Mastocytosis complicating pregnancy 80. Obstet. Gynecol. 95 (2000) 391-395
386. Worobec A.S., Kirshenbaum A.S., Schwartz L.B., and Metcalfe D.D. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk. Lymphoma 22 (1996) 501-508
387. Worobec A.S., Semere T., Nagata H., and Metcalfe D.D. Clinical correlates of the presence of the Asp816Val c-Kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 83 (1998) 2120-2129
388. Wu H., Klingmuller U., Besmer P., and Lodish H.F. Interaction of the erythropoietin and stem-cell-factor receptors. Nature 377 (1995) 242-246
389. Yavuz A.S., Lipsky P.E., Yavuz S., Metcalfe D.D., and Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-Kit gene. Blood 100 (2002) 661-665
390. Yee N.S., Hsiau C.W., Serve H., Vosseller K., and Besmer P. Mechanism of downregulation of c-Kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3′-kinase, and protein kinase C. J. Biol. Chem. 269 (1994) 31991-31998
391. Zhang Y., Ramos B.F., and Jakschik B.A. Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science 258 (1992) 1957-1959
392. Zsebo K.M., Williams D.A., Geissler E.N., Broudy V.C., Martin F.H., Atkins H.L., Hsu R.Y., Birkett N.C., Okino K.H., and Murdock D.C. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-Kit tyrosine kinase receptor. Cell 63 (1990) 213-224